Life Sciences

  • November 25, 2025

    Judge Hands SEC Win In Pharma Co.'s CBD Investor Fraud Case

    A California federal judge has granted the U.S. Securities and Exchange Commission an early win in its suit against Vivera Pharmaceuticals, its CEO and affiliate Sentar Pharmaceuticals, finding they misled investors about the company's rights to key cannabinoid drug-delivery technology and about how investor money would be spent.

  • November 25, 2025

    MVP: Hogan Lovells' Mahvesh A. Qureshi

    Mahvesh A. Qureshi, a life sciences partner at Hogan Lovells, advised her client through a deal to acquire Anthos Therapeutics, a biopharmaceutical company that developed a unique stroke treatment, in a transaction that could total $3.1 billion, and led Merck on its up to $1.3 billion purchase of a novel autoimmune drug, earning her a spot as one of the 2025 Law360 Life Sciences MVPs.

  • November 25, 2025

    NRDC Tells 9th Circ. EPA Would 'Neuter' Public TSCA Rights

    The Natural Resources Defense Council has asked the Ninth Circuit to reject the U.S. Environmental Protection Agency's narrow reading of citizen enforcement rights under the Toxic Substances Control Act, saying it would unfairly restrict challenges to agency inaction.

  • November 24, 2025

    Mass. Judge Says States Can Fight Planned Parenthood Cuts

    A Massachusetts federal judge on Monday chided a Trump administration lawyer for continuing to argue that a coalition of states lacks standing to seek to block what it says is the effective defunding of Planned Parenthood, even as it only just received a lengthy list of new requirements for Medicaid reimbursement.

  • November 24, 2025

    DOJ Demand For Pa. Transgender Patient Records Blocked

    A Pennsylvania federal judge partially quashed part of a U.S. Department of Justice subpoena seeking health records for minors receiving gender-affirming care at The Children's Hospital of Philadelphia, ruling that the department lacked the statutory authority "for a rambling exploration" of medical files involving state-sanctioned medical care.

  • November 24, 2025

    Full Fed. Circ. Rejects Bayer Petition In Xarelto Patent Case

    The full Federal Circuit on Monday declined a petition from German pharmaceutical giant Bayer asking the appeals court to take a look at reviving patent claims related to its blood thinner medication Xarelto.

  • November 24, 2025

    Hi-Tech Pharma CEO Beats Most Of Feds' Fraud Case

    A Georgia federal jury acquitted Hi-Tech Pharmaceuticals' chief executive on the bulk of the conspiracy, fraud and money laundering charges leveled against him, rejecting allegations that he cheated his customers by drawing up bogus quality certificates.

  • November 24, 2025

    Israeli Co. Can't Expand Contract Breach Suit Over $25M Deal

    An Israeli smart packaging company can't enlarge a North Carolina Business Court contract breach suit, a judge ruled Monday, saying the amendment would "wholly transform" the case and prejudice defendant Sealed Air Corp.

  • November 24, 2025

    Biotechs Go To Del. Chancery Over Cancer Drug Rights

    A contract battle has broken out in the Delaware Chancery Court between two biotechs, each accusing the other of materially breaching a decade-old collaboration agreement governing rights to the cancer drug Jemperli.

  • November 24, 2025

    FTC Abandons In-House GTCR Merger Case After Court Loss

    The Federal Trade Commission formally dropped its administrative case challenging GTCR BC Holdings LLC's acquisition of a medical coatings supplier after an Illinois federal judge refused to put the deal on hold.

  • November 24, 2025

    MVP: Cooley's Charity Williams

    Charity Williams, a partner in Cooley LLP's life sciences corporate partnering and licensing practice, guided transformative pharmaceutical deals in 2025, including Capstan Therapeutics' $2.1 billion sale to AbbVie, Esobiotec's $1 billion sale to AstraZeneca and Advanced Instruments' $2.2 billion acquisition of Nova Biomedical, earning her a spot as one of the 2025 Law360 Life Sciences MVPs.

  • November 24, 2025

    Ophthalmic Co. Hits Ch. 11 With $64M Debt, Eyeing Sale

    Clearside Biomedical, a company developing treatments for eye diseases, has filed for Chapter 11 protection in Delaware bankruptcy court with $64 million in debt, saying it will attempt to sell its business during the case.

  • November 24, 2025

    Justices Skip Appeal Challenging Denial Of Color TM

    The U.S. Supreme Court on Monday declined an appeal from a medical supply company challenging a Federal Circuit ruling that rejected its bid to register a color trademark for dark green surgical gloves.

  • November 24, 2025

    Justices Refuse Drug Price-Fixing Class Action

    The U.S. Supreme Court said Monday that it will not review the Fourth Circuit's decision to back the dismissal of a proposed class action accusing drugmakers of conspiring and inflating the price of a medication for Huntington's disease.

  • November 21, 2025

    Squires Issues 57 More PTAB Denials, Broken Out By Type

    U.S. Patent and Trademark Office Director John Squires has rejected another 57 petitions challenging patents under the America Invents Act and for the first time differentiated between those denied for discretionary reasons and those denied on the merits.

  • November 21, 2025

    DC Judge Axes Teva Challenge To Drug Price Program

    A D.C. federal judge tossed a challenge by Teva Pharmaceuticals to the Medicare drug price negotiation program, marking the latest in a series of losses by drugmakers and trade groups seeking to upend the program.

  • November 21, 2025

    Applied Therapeutics Investors Get 1st OK For $15M Deal

    Biopharmaceutical company Applied Therapeutics Inc. and its investors have received initial approval of a deal that will end claims related to a 2024 new drug application, including a cash settlement of $15 million.

  • November 21, 2025

    PBMs Say Gov't Benefits From Drug Rebates FTC Condemns

    Caremark Rx, Express Scripts and OptumRx have been given permission to seek documents they say will show the government benefits from the same type of prescription drug rebating activity that's being targeted by the Federal Trade Commission's insulin pricing case.

  • November 21, 2025

    'No Evidence' New Info Backs J&J Unit's Libel Suit, Court Told

    A doctor being sued by Johnson & Johnson's bankrupt talc subsidiary pushed back on the unit's bid to revive its trade libel claim over a scientific article she wrote linking asbestos in talc to mesothelioma, arguing it failed to cite any evidence that undermines the court's finding that the article was a nonactionable statement of scientific opinion.

  • November 21, 2025

    DLA Piper Adds Fenwick Emerging Growth, VC Expert In LA

    DLA Piper is boosting its corporate team, bringing in a Fenwick & West LLP venture capital ace as a partner in its Los Angeles office.

  • November 21, 2025

    Bausch Health Financial Stability Suit Permanently Dismissed

    A New Jersey federal judge has dismissed for good a class action against Bausch Health Cos. Inc. and its top brass over claims that they misled shareholders about threats to the company's financial stability, finding that the second amended complaint includes inactionable challenged statements and fails to state a claim.

  • November 21, 2025

    1st Circ. Clears IT Co. In Suit Over Zoll Patient Data Breach

    An information technology company cannot be held liable for a data breach exposing the health information of patients of a unit of medical device maker Zoll Medical Corp, the First Circuit ruled, because the two companies did not have a business relationship permitting them to hold one responsible for another's conduct.

  • November 20, 2025

    Texas Sues Bristol-Myers For Alleged Drug Misrepresentations

    The Texas Office of the Attorney General sued pharmaceutical companies Bristol-Myers Squibb and Sanofi in Texas state court, claiming Thursday the companies failed to disclose that a lucrative blood thinner used to prevent heart attacks and strokes does not work as well on certain minority patients.

  • November 20, 2025

    Invisalign-Maker's Sweetened $32M Antitrust Payout OK'd

    A California federal judge who previously rejected Invisalign-maker Align Technology's $27.5 million antitrust deal with SmileDirectClub buyers because it included a coupon program said Thursday he will approve a revised deal, which provides for an all-cash $31.75 million payout.

  • November 20, 2025

    Pharma Cos. Seek Early Win In States' Price-Fixing Lawsuit

    A collection of states failed to prove an overarching conspiracy among 25 separate pharmaceutical companies to fix the prices of generic drugs, most of them dermatology formulations, the drugmakers argued Wednesday in support of a bid for an early win on one element of dozens of antitrust claims.

Expert Analysis

  • AG Watch: Texas Embraces The MAHA Movement

    Author Photo

    Attorneys at Kelley Drye examine Texas Attorney General Ken Paxton's actions related to the federal Make America Healthy Again movement, and how these actions hinge on representations or omissions by the target companies as opposed to specific analyses of the potential health risks.

  • Opinion

    Bar Exam Reform Must Expand Beyond A Single Updated Test

    Author Photo

    Recently released information about the National Conference of Bar Examiners’ new NextGen Uniform Bar Exam highlights why a single test is not ideal for measuring newly licensed lawyers’ competency, demonstrating the need for collaborative development, implementation and reform processes, says Gregory Bordelon at Suffolk University.

  • The Patent Eligibility Eras Tour: 11 Years Of Post-Alice Tumult

    Author Photo

    A survey of recent twists and turns in patent eligibility law highlights the confusion created by the U.S. Supreme Court's 2014 Alice decision and reveals that the continually shifting standards have begun to diverge in fundamental ways between the Federal Circuit and the U.S. Patent and Trademark Office, says Michael Shepherd at Fish & Richardson.

  • Location Data And Online Tracking Trends To Watch

    Author Photo

    Regulators and class action plaintiffs are increasingly targeting companies' use of online tracking technologies and geolocation data in both privacy enforcement and litigation, so organizations should view compliance as a dynamic, cross-functional responsibility as scrutiny becomes increasingly aggressive and multifaceted, say attorneys at Arnold & Porter.

  • A Simple Way Courts Can Help Attys Avoid AI Hallucinations

    Author Photo

    As attorneys increasingly rely on generative artificial intelligence for legal research, courts should consider expanding online quality control programs to flag potential hallucinations — permitting counsel to correct mistakes and sparing judges the burden of imposing sanctions, say attorneys at Lankler Siffert & Wohl and Connors.

  • DOJ Consumer Branch's End Leaves FDA Litigation Questions

    Author Photo

    With the dissolution of the U.S. Department of Justice's Consumer Protection Branch set to occur by Sept. 30, companies must carefully monitor how responsibility is reallocated for civil and criminal enforcement cases related to products regulated by the U.S. Food and Drug Administration, say attorneys at Foley & Lardner.

  • The Evolving Legal Landscape For THC-Infused Beverages

    Author Photo

    A recent Eighth Circuit ruling, holding that states may restrict the sale of intoxicating hemp-derived products without violating federal law, combined with ongoing regulatory uncertainty at both the federal and state levels, could alter the trajectory of the THC-infused beverage market, say attorneys at Pashman Stein.

  • Series

    Creating Botanical Art Makes Me A Better Lawyer

    Author Photo

    Pressing and framing plants that I grow has shown me that pursuing an endeavor that brings you joy can lead to surprising benefits for a legal career, including mental clarity, perspective and even a bit of humility, says Douglas Selph at Morris Manning.

  • Opinion

    The Legal Education Status Quo Is No Longer Tenable

    Author Photo

    As underscored by the fallout from California’s February bar exam, legal education and licensure are tethered to outdated systems, and the industry must implement several key reforms to remain relevant and responsive to 21st century legal needs, says Matthew Nehmer at The Colleges of Law.

  • 2nd Circ. Reinforces Consensus On Vacating Foreign Awards

    Author Photo

    In Molecular Dynamics v. Spectrum Dynamics Medical, the Second Circuit recently affirmed that federal district courts do not possess subject matter jurisdiction to vacate foreign arbitral awards, strengthening this consensus across the circuits most active in recognition and enforcement actions, says Ed Mullins at Reed Smith.

  • E-Discovery Quarterly: Rulings On Relevance Redactions

    Author Photo

    In recent cases addressing redactions that parties sought to apply based on the relevance of information — as opposed to considerations of privilege — courts have generally limited a party’s ability to withhold nonresponsive or irrelevant material, providing a few lessons for discovery strategy, say attorneys at Sidley.

  • How DOJ's New Data Security Rules Leave HIPAA In The Dust

    Author Photo

    The U.S. Department of Justice's recently effective data security requirements carry profound implications for how healthcare providers collect, store, share and use data — and approach vendor oversight — that go far beyond the Health Insurance Portability and Accountability Act, say attorneys at Nelson Mullins.

  • Opinion

    Section 1983 Has Promise After End Of Nationwide Injunctions

    Author Photo

    After the U.S. Supreme Court recently struck down the practice of nationwide injunctions in Trump v. Casa, Section 1983 civil rights suits can provide a better pathway to hold the government accountable — but this will require reforms to qualified immunity, says Marc Levin at the Council on Criminal Justice.

  • Trump's 2nd Term Puts Merger Remedies Back On The Table

    Author Photo

    In contrast with the Biden administration, the second Trump administration has signaled a renewed willingness to resolve merger enforcement concerns through remedies from the outset, particularly when the proposed fix is structural, clearly addresses the harm and does not require burdensome oversight, say attorneys at Cooley.

  • Patent Ambiguity Persists After Justices Nix Eligibility Appeal

    Author Photo

    The Supreme Court recently declined to revisit the contentious framework governing patent eligibility by denying certiorari in Audio Evolution Diagnostics v. U.S., suggesting a necessary recalibration of both patent application and litigation strategies, say attorneys at Skadden.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.